Swiss pharmaceutical market entry: choose the right operating model

Key takeaways

• Treat authorisation, establishment licensing, supply and reimbursement as separate but connected decisions.
• An EMA or European Commission authorisation does not automatically permit marketing in Switzerland.
• Choose the Swiss MAH and licence model before fixing the physical supply chain and launch date.
• Build one evidence-based launch gate covering regulatory, safety, quality, supply and market access readiness.

What does Swiss pharmaceutical market entry actually require?

A useful plan starts by separating five layers. Swissmedic authorises the medicinal product. Swissmedic also licenses the legal entities and sites that manufacture, import, conduct wholesale trade or release batches for the Swiss market. The marketing authorisation holder, or MAH, owns the product authorisation and its lifecycle obligations. The supply chain moves only batches released under the Swiss model. The Federal Office of Public Health, or FOPH, makes the separate decision on routine outpatient reimbursement through the Specialities List.

This distinction prevents a common planning error: using one milestone as a proxy for the whole launch. A positive EU decision is valuable regulatory evidence, but it is not a Swiss authorisation. A signed distribution agreement does not prove that the importer and holder have the right licence scope. Swissmedic authorisation does not itself secure reimbursement. A practical market-entry programme therefore assigns an owner, evidence package and go or no-go criterion to each layer.

Sources and further reading: [1][2][3][6]

Which operating model fits the launch?

Compare three practical models. An own Swiss affiliate offers direct control but requires an eligible Swiss entity, the right establishment-licence scope, responsible functions and durable local governance. A qualifying external MAH can reduce fixed infrastructure while the product owner governs performance through contracts, access rights and exit provisions. A distributor or licensee may combine authorisation ownership with commercial execution, but a distributor acting only as a sales or logistics party is not automatically the Swiss MAH.

Choose by evidence rather than a generic preference for speed or control. Test portfolio size, expected launch duration, pricing authority, data access, pharmacovigilance and quality interfaces, conflicts with the partner portfolio and the ability to transfer the authorisation later. The table is our planning framework. Legal and licence suitability must still be checked for the exact entity and activities.

Sources and further reading: [1][3]

Which Swissmedic authorisation route fits the product?

The route depends on the product, its active substance, foreign regulatory history and available assessment records. Under Article 13 of the Therapeutic Products Act, Swissmedic may consider assessments from a country with a comparable control system when the conditions are met. The applicant must request this route explicitly and provide the current decision and assessment report from the reference authority. Swissmedic still makes the Swiss decision and checks the Swiss-specific requirements.

Article 13 should be treated as a reliance pathway, not automatic recognition and not a promise of a light dossier. Swissmedic's guidance calls for the full documentation in CTD format, the reference authority's country-specific Module 1 and a Swiss Module 1. The scientific content, approved indication, manufacturing chain and post-authorisation changes need a detailed comparability review. If the foreign and Swiss applications diverge, the team should identify early whether the difference is permitted in the chosen pathway or needs another route.

• Confirm the intended reference authority and availability of its final assessment report.
• Reconcile every approved change made after the foreign authorisation decision.
• Document negative, withdrawn, suspended or materially different foreign decisions.
• Test product, indication and manufacturing comparability before setting the filing plan.

Sources and further reading: [1][2]

How should the Swiss MAH and establishment licence model be chosen?

The applicant for a Swiss marketing authorisation must meet the conditions in Article 10 TPA. These include the relevant authorisation to manufacture, import or conduct wholesale trade and a registered address, registered office or branch in Switzerland. A foreign company can therefore assess an appropriately structured Swiss entity or a qualifying external holder model. A Swiss address alone is not the operating model, because the licence scope, responsible persons, quality system and access to records must support the intended activities.

Check the exact legal entity in SwissGMDP, including its sites and licensed activities. Then map which entity will hold the authorisation, employ or engage the Responsible Person for market release, import the goods, store them and supply customers. Outsourced operations require suitable licensed parties, written quality agreements and oversight. Final market-release and recall responsibility remains with the MAH, so the commercial contract must not give another party a veto over a necessary safety or quality action.

Sources and further reading: [1][3][5]

What Swiss dossier, product information and language work is needed?

Global CTD content can provide the scientific core, but the Swiss submission needs a current lifecycle and Swiss administrative layer. The working team should reconcile Modules 2 to 5 against the selected foreign submission, build Swiss Module 1, confirm manufacturer and licence evidence, and identify Swiss-specific quality, pharmacopoeial and risk-management requirements. Existing eCTD sequence history should be preserved and made available to the future holder so that later variations and transfers remain manageable.

Product information and packaging are separate deliverables, not a final artwork exercise. Swissmedic's guidance requires information for healthcare professionals in German, French and Italian, with the holder responsible for translations. Packaging generally needs at least two official Swiss languages, subject to defined exceptions. Translation governance should include medical and regulatory review, version control and enough time to align the approved wording with packaging, risk-minimisation materials and launch stock.

Sources and further reading: [2][7][8]

When should pharmacovigilance, batch release and import be designed?

Design them before submission and supply contracting, not after approval. Current Swissmedic guidance requires a qualified Responsible Person for Pharmacovigilance, or RPV, and a qualified deputy. Safety responsibilities begin from the marketing authorisation application. An external RPV is possible and need not reside in Switzerland, but written responsibilities, at least one official-language capability, a quality-assured translation process and documented MAH oversight are required.

For supply, distinguish manufacturer technical release from Swiss market release. The MAH's Responsible Person decides whether a batch can be placed on the Swiss market under Article 13 MPLO. Import, storage and distribution then follow the applicable establishment licence and GDP controls. Physical operations may be contracted to a pre-wholesaler, yet the MAH retains the final release decision, product integrity oversight and recall accountability. Product categories subject to official authority batch release need an additional product-specific step.

Sources and further reading: [4][5]

How do reimbursement and launch timing fit the entry plan?

If routine outpatient compulsory-insurance reimbursement is commercially important, plan the FOPH workstream alongside Swissmedic. Specialities List inclusion is a separate decision based on effectiveness, appropriateness and economic efficiency. The price assessment uses therapeutic comparison with reimbursed alternatives and a foreign price comparison. A limitation can narrow the reimbursed population, prescriber, quantity or conditions, so the intended value proposition must align with the final Swiss indication and practical use.

FOPH processes allow defined pre-authorisation coordination and an Early Access route for suitable cases, but parallel work is not a guarantee of simultaneous decisions. The better management tool is a launch gate that records the evidence and remaining risk in each workstream. Our table is a suggested planning framework, not an authority requirement. It helps management distinguish a filing-ready product from a supply-ready or reimbursed launch.

Sources and further reading: [5][6]